Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.

Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using minimally invasive procedures.In this triple-blind, placebo-co...

Full description

Bibliographic Details
Main Authors: Oscar Fernández, Guillermo Izquierdo, Victoria Fernández, Laura Leyva, Virginia Reyes, Miguel Guerrero, Antonio León, Carlos Arnaiz, Guillermo Navarro, Maria Dolores Páramo, Antonio De la Cuesta, Bernat Soria, Abdelkrim Hmadcha, David Pozo, Rafael Fernandez-Montesinos, Maria Leal, Itziar Ochotorena, Patricia Gálvez, Maria Angeles Geniz, Francisco Javier Barón, Rosario Mata, Cristina Medina, Carlos Caparrós-Escudero, Ana Cardesa, Natividad Cuende, Research Group Study EudraCT 2008-004015-35
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5955528?pdf=render

Internet

http://europepmc.org/articles/PMC5955528?pdf=render

Similar Items